Safety, immunogenicity and protective efficacy in mice of a new cell-cultured Lister smallpox vaccine candidate

Vaccine

Volumn 25, Issue 49, 2007, Pages 8290-8297

  Ferrier Rembert, Audrey ^a   Drillien, Robert ^c,d   Meignier, Bernard ^b   Garin, Daniel ^a   Crance, Jean Marc ^a  

^a Centre de Recherches   (France)

^b SANOFI PASTEUR   (France)

^c INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^d UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Cowpox; Immunogenicity; Mice; Protection; Smallpox; Smallpox vaccine; Vaccinia; Variola

Indexed keywords

GAMMA INTERFERON; NEUTRALIZING ANTIBODY; SMALLPOX VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; COWPOX VIRUS; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLOW CYTOMETRY; HUMORAL IMMUNITY; IMMUNOGENICITY; INOCULATION; LD 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; SMALLPOX; SMALLPOX VIRUS; STATISTICAL ANALYSIS; SURVIVAL TIME; VACCINIA VIRUS; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, VIRAL; BIOTERRORISM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; CHICK EMBRYO; COWPOX; COWPOX VIRUS; FEMALE; HUMANS; INTERFERON TYPE II; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; SMALLPOX; SMALLPOX VACCINE; VACCINIA VIRUS; VERO CELLS;

EID: 36048949912     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.09.050     Document Type: Article

References (24)

1. Fenner F., Henderson D.A., Arita I., Jezek Z., and Ladnyi I.D. Smallpox and its eradication (1988), WHO, Geneva p. 1460
2. Fenner F. Smallpox, "the most dreadful scourge of the human species". Its global spread and recent eradication (2). Med J Aust 141 11 (1984) 728-735
3. Garcel A., Crance J.M., Drillien R., Garin D., and Favier A.L. Genomic sequence of a clonal isolate of the vaccinia virus Lister strain employed for smallpox vaccination in France and its comparison to other orthopoxviruses. J Gen Virol 88 Pt 7 (2007) 1906-1916
4. Monath T.P., Caldwell J.R., Mundt W., Fusco J., Johnson C.S., Buller M., et al. ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain) a second-generation smallpox vaccine for biological defense. Int J Infect Dis 8 Suppl. 2 (2004) S31-S44
5. Weltzin R., Liu J., Pugachev K.V., Myers G.A., Coughlin B., Blum P.S., et al. Clonal vaccinia virus grown in cell culture as a new smallpox vaccine. Nat Med 9 9 (2003) 1125-1130
6. Coulibaly S., Bruhl P., Mayrhofer J., Schmid K., Gerencer M., and Falkner F.G. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection. Virology 341 1 (2005) 91-101
7. Phelps A., Gates A.J., Hillier M., Eastaugh L., and Ulaeto D.O. Comparative efficacy of replicating smallpox vaccine strains in a Murine Challenge Model. Vaccine 23 27 (2005) 3500-3507
8. Kenner J., Cameron F., Empig C., Jobes D.V., and Gurwith M. LC16m8: an attenuated smallpox vaccine. Vaccine 24 47-48 (2006) 7009-7022
9. Ferrier-Rembert A., Drillien R., Tournier J.N., Garin D., and Crance J.M. Intranasal cowpox virus infection of the mouse as a model for preclinical evaluation of smallpox vaccines. Vaccine 25 25 (2007) 4809-4817
10. + T cells play a pivotal role in the control of cowpox virus infection in mice. Viral Immunol 20 1 (2007) 214-220
11. Scaramozzino N., Ferrier-Rembert A., Favier A.L., Rothlisberger C., Richard S., Crance J.M., et al. Real-time PCR to identify variola virus or other human pathogenic orthopox viruses. Clin Chem 53 4 (2007) 606-613
12. Reed L.J., and Muench L.H. A simple method of estimating fifty percent end points. Am J Hyg 27 (1938) 493-497
13. Fuchs F, Poirier B, Leparc-Goffart I, Buchheit KH. Collaborative study for the Establishment of the Ph. Eur. BRP Batch 1 for Anti-Vaccinia Immunoglobulin. In: EDQM, editor. Pharmeuropia Bio-The biological standardisation programme, 2005. p. 8-13.
14. Leparc-Goffart I., Poirier B., Garin D., Tissier M.H., Fuchs F., and Crance J.M. Standardization of a neutralizing anti-vaccinia antibodies titration method: an essential step for titration of vaccinia immunoglobulins and smallpox vaccines evaluation. J Clin Virol 32 1 (2005) 47-52
15. Tournier J.N., Hellmann A.Q., Lesca G., Jouan A., Drouet E., and Mathieu J. Fever-like thermal conditions regulate the activation of maturing dendritic cells. J Leukoc Biol 73 4 (2003) 493-501
16. Henderson D.A., and Moss B. Smallpox and vaccinia. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccines. 3rd ed. (1999), Saunders, WB, Philadelphia 74-97
17. Gangemi J.D., and Sharp D.G. Particle heterogeneity in vaccinia virus populations during passage. Virology 85 (1978) 262-270
18. EMEA. Note for guidance on the development of vaccinia virus based vaccines against smallpox. 2002.
19. Rosenthal S.R., Merchlinsky M., Kleppinger C., and Goldenthal K.L. Developing new smallpox vaccines. Emerg Infect Dis 7 6 (2001) 920-926
20. Smee D.F., Bailey K.W., and Sidwell R.W. Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir. Antivir Chem Chemother 12 1 (2001) 71-76
21. Belyakov I.M., Earl P., Dzutsev A., Kuznetsov V.A., Lemon M., Wyatt L.S., et al. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci USA 100 16 (2003) 9458-9463
22. Meseda C.A., Garcia A.D., Kumar A., Mayer A.E., Manischewitz J., King L.R., et al. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model. Virology 339 3 (2005) 164-175
23. Phelps A., Gates A.J., Hillier M., Eastaugh L., and Ulaeto D.O. Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine. Vaccine 25 1 (2007) 34-42
24. Wyatt L.S., Earl P.L., Eller L.A., and Moss B. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci USA 101 13 (2004) 4590-4595